Effects of Thalidomide on the Expression of Adhesion Molecules in Rat Liver Cirrhosis

Lv, Peng; Paul, Shelley Chireyath; Xiao, Yanjv; Liu, Shiquan; Luo, Hesheng

doi:https://doi.org/10.1155/MI/2006/93253

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Research Communication | Open Access

Volume 2006 | Article ID 093253 | https://doi.org/10.1155/MI/2006/93253

Effects of Thalidomide on the Expression of Adhesion Molecules in Rat Liver Cirrhosis

Peng Lv,¹Shelley Chireyath Paul,¹Yanjv Xiao,¹Shiquan Liu,¹and Hesheng Luo¹

Received15 Dec 2005

Accepted13 Mar 2006

Published11 May 2006

Abstract

This study was to evaluate the effects of thalidomide on expression of adhesion molecules in liver cirrhosis. The cirrhosis was induced in Wistar rats by intraperitoneal injection of CCl4, and thalidomide (10 mg/kg/day or 100 mg/kg/day) was given by intragastric administration for 8 weeks. Liver histopathology and immunohistochemistry were significantly improved and the expressions of ICAM-1, VCAM-1, E-selectin, and TNF-α mRNA and protein were decreased significantly in rats treated with a high dose of thalidomide. Close positive correlation was observed in the expression of the TNF-α mRNA and that of ICAM-1, VCAM-1, and E-selectin mRNA, respectively. These results indicate that thalidomide exerts its effect on the downregulation of adhesion molecules via TNF-α signaling pathway to inhibit liver fibrosis.

References

B Madan, A K Prasad, V S Parmar, and B Ghosh, “1,4-Dihydroxyxanthone modulates the adhesive property of endothelial cells by inhibiting intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin,” Bioorganic and Medicinal Chemistry, vol. 12, no. 6, pp. 1431–1437, 2004.
View at: Google Scholar
R Volpes, J J Van den Oord, and V J Desmet, “Immunohistochemical study of adhesion molecules in liver inflammation,” Hepatology, vol. 12, no. 1, pp. 59–65, 1990.
View at: Google Scholar
C M Bruno, C Sciacca, D Cilio et al., “Circulating adhesion molecules in patients with virus-related chronic diseases of the liver,” World Journal of Gastroenterology, vol. 11, no. 29, pp. 4566–4569, 2005.
View at: Google Scholar
J A Girón-González, C Martínez-Sierra, C Rodriguez-Ramos et al., “Adhesion molecules as a prognostic marker of liver cirrhosis,” Scandinavian Journal of Gastroenterology, vol. 40, no. 2, pp. 217–224, 2005.
View at: Google Scholar
H Yokomori, M Oda, M Ogi et al., “Expression of adhesion molecules on mature cholangiocytes in canal of Hering and bile ductules in wedge biopsy samples of primary biliary cirrhosis,” World Journal of Gastroenterology, vol. 11, no. 28, pp. 4382–4389, 2005.
View at: Google Scholar
A Panasiuk, D Prokopowicz, and B Panasiuk, “Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C,” World Journal of Gastroenterology, vol. 10, no. 24, pp. 3639–3642, 2004.
View at: Google Scholar
J W Ho, R T Poon, C S Tong, and S T Fan, “Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 10, no. 14, pp. 2014–2018, 2004.
View at: Google Scholar
H Yokomori, M Oda, K Yoshimura et al., “Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 protein and messenger RNA in primary biliary cirrhosis,” Internal Medicine, vol. 42, no. 10, pp. 947–954, 2003.
View at: Google Scholar
C Pata, A Yazar, E Altintas et al., “Serum levels of intercellular adhesion molecule-1 and nitric oxide in patients with chronic hepatitis related to hepatitis C virus: connection fibrosis,” Hepato-Gastroenterology, vol. 50, no. 51, pp. 794–797, 2003.
View at: Google Scholar
A Abdalla, A-A G Sheesha, M Shokeir et al., “Serum intercellular adhesion molecule-I in children with chronic liver disease: relationship to disease activity,” Digestive Diseases and Sciences, vol. 47, no. 6, pp. 1206–1208, 2002.
View at: Google Scholar
H Kobayashi, K Horikoshi, L Long, A Yamataka, G J Lane, and T Miyano, “Serum concentration of adhesion molecules in postoperative biliary atresia patients: relationship to disease activity and cirrhosis,” Journal of Pediatric Surgery, vol. 36, no. 8, pp. 1297–1301, 2001.
View at: Google Scholar
F Capra, E De Maria, C Lunardi et al., “Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: a prognostic marker for responses to interferon treatment,” Journal of Infectious Diseases, vol. 181, no. 2, pp. 425–431, 2000.
View at: Google Scholar
F Tacke, P Schöffski, C Trautwein et al., “Plasma P-selectin levels are elevated in patients with chronic liver disease,” Blood Coagulation and Fibrinolysis, vol. 14, no. 4, pp. 319–325, 2003.
View at: Google Scholar
M Cervello, L Virruso, G Lipani et al., “Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 126, no. 6, pp. 345–351, 2000.
View at: Google Scholar
T Eriksson, S Björkman, and P Höglund, “Clinical pharmacology of thalidomide,” European Journal of Clinical Pharmacology, vol. 57, no. 5, pp. 365–376, 2001.
View at: Google Scholar
S V Rajkumar, “Current status of thalidomide in the treatment of cancer,” Oncology (Huntington), vol. 15, no. 7, pp. 867–874, 877–879, 2001.
View at: Google Scholar
B Settles, A Stevenson, K Wilson et al., “Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TN F- $\alpha$ agent thalidomide,” Cellular and Molecular Biology (Noisy-le-Grand), vol. 47, no. 7, pp. 1105–1114, 2001.
View at: Google Scholar
C Meierhofer, S Dunzendorfer, and C J Wiedermann, “Theoretical basis for the activity of thalidomide,” BioDrugs, vol. 15, no. 10, pp. 681–703, 2001.
View at: Google Scholar
L García, I Hernández, A Sandoval et al., “Pirfenidone effectively reverses experimental liver fibrosis,” Journal of Hepatology, vol. 37, no. 6, pp. 797–805, 2002.
View at: Google Scholar
M Pinzani and K Rombouts, “Liver fibrosis: from the bench to clinical targets,” Digestive and Liver Disease, vol. 36, no. 4, pp. 231–242, 2004.
View at: Google Scholar
J Garcia-Bañuelos, F Siller-Lopez, A Miranda, L K Aguilar, E Aguilar-Cordova, and J Armendariz-Borunda, “Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion,” Gene Therapy, vol. 9, no. 2, pp. 127–134, 2002.
View at: Google Scholar
D C Rockey, “Antifibrotic therapy in chronic liver disease,” Clinical Gastroenterology and Hepatology, vol. 3, no. 2, pp. 95–107, 2005.
View at: Google Scholar
N Enomoto, Y Takei, M Hirose, T Kitamura, K Ikejima, and N Sato, “Protective effect of thalidomide on endotoxin-induced liver injury,” Alcoholism: Clinical and Experimental Research, vol. 27, no. 8 suppl, pp. 2S–6S, 2003.
View at: Google Scholar
A S Austin, Y R Mahida, D Clarke, S D Ryder, and J G Freeman, “A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis,” Alimentary Pharmacology and Therapeutics, vol. 19, no. 1, pp. 79–88, 2004.
View at: Google Scholar
Y Z Patt, M M Hassan, R D Lozano et al., “Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial,” Cancer, vol. 103, no. 4, pp. 749–755, 2005.
View at: Google Scholar
C Hsu, J C-H Cheng, and A-L Cheng, “Recent advances in non-surgical treatment for advanced hepatocellular carcinoma,” Journal of the Formosan Medical Association, vol. 103, no. 7, pp. 483–495, 2004.
View at: Google Scholar
T-E Wang, C-R Kao, S-C Lin et al., “Salvage therapy for hepatocellular carcinoma with thalidomide,” World Journal of Gastroenterology, vol. 10, no. 5, pp. 649–653, 2004.
View at: Google Scholar
A Thiele, R Bang, M Gütschow et al., “Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide,” European Journal of Pharmacology, vol. 453, no. 2-3, pp. 325–334, 2002.
View at: Google Scholar
J-P Raufman and L W Lamps, “Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C,” American Journal of Gastroenterology, vol. 96, no. 11, pp. 3209–3211, 2001.
View at: Google Scholar
P Muriel, E Fernández-Martínez, V Pérez-Álvarez et al., “Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat,” European Journal of Gastroenterology and Hepatology, vol. 15, no. 9, pp. 951–957, 2003.
View at: Google Scholar
T-S Yeh, Y-P Ho, S-F Huang, J-N Yeh, Y-Y Jan, and M-F Chen, “Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from cirrhosis in rats,” Journal of Hepatology, vol. 41, no. 4, pp. 606–612, 2004.
View at: Google Scholar
P P Simeonova, R M Gallucci, T Hulderman et al., “The role of tumor necrosis factor- $\alpha$ in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride,” Toxicology and Applied Pharmacology, vol. 177, no. 2, pp. 112–120, 2001.
View at: Google Scholar
K Sudo, Y Yamada, H Moriwaki, K Saito, and M Seishima, “Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice,” Cytokine, vol. 29, no. 5, pp. 236–244, 2005.
View at: Google Scholar
R JR Singh, J C Mason, E A Lidington et al., “Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3,” Cardiovascular Research, vol. 67, no. 1, pp. 39–49, 2005.
View at: Google Scholar
K Maeda, K Yoshida, I Ichimiya, and M Suzuki, “Dexamethasone inhibits tumor necrosis factor- $\alpha$ -induced cytokine secretion from spiral ligament fibrocytes,” Hearing Resaerch, vol. 202, no. 1-2, pp. 154–160, 2005.
View at: Google Scholar
C-H Woo, J-H Lim, and J-H Kim, “VCAM-1 upregulation via PKC $\delta$ -p38 kinase-linked cascade mediates the TNF- $\alpha$ -induced leukocyte adhesion and emigration in the lung airway epithelium,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 288, no. 2 32-2, pp. L307–L316, 2005.
View at: Google Scholar
N Kumagai, K Fukuda, Y Fujitsu, and T Nishida, “Expression of functional ICAM-1 on cultured human keratocytes induced by tumor necrosis factor- $\alpha$ ,” Japanese Journal of Ophthalmology, vol. 47, no. 2, pp. 134–141, 2003.
View at: Google Scholar
M Sasaki, D Ostanin, J W Elrod et al., “TNF- $\alpha$ -induced endothelial cell adhesion molecule expression is cytochrome P-450 monooxygenase dependent,” American Journal of Physiology - Cell Physiology, vol. 284, no. 2 53-2, pp. C422–C428, 2003.
View at: Google Scholar
M Schäefers, C Schmidt, C Vogel, K V Toyka, and C Sommer, “Tumor necrosis factor- $\alpha$ (TNF) regulates the expression of ICAM-1 predomonantly through TNF receptor 1 after chronic constriction injury of mouse sciatic nerve,” Acta Neuropathologica (Berlin), vol. 104, no. 2, pp. 197–205, 2002.
View at: Google Scholar
N M Dagia, N Harii, A E Meli et al., “Phenyl methimazole inhibits TNF- $\alpha$ -induced VCAM-1 expression in an IFN regulatory factor-1-dependent manner and reduces monocytic cell adhesion to endothelial cells,” Journal of Immunology, vol. 173, no. 3, pp. 2041–2049, 2004.
View at: Google Scholar
C H Hang, J-X Shi, J-S Li, W Wu, and X Y Hong, “Concomitant upregulation of nuclear factor- $\kappa$ B activity, proinflammatory cytokines and ICAM-1 in the injured brain after cortical contusion trauma in a rat model,” Neurology India, vol. 53, no. 3, pp. 312–317, 2005.
View at: Google Scholar
E-W Son, S-J Mo, D-K Rhee, and S Pyo, “Vitamin C blocks TNF- $\alpha$ -induced NF- $\kappa$ B activation and ICAM-1 expression in human neuroblastoma cells,” Archives of Pharmacal Research, vol. 27, no. 10, pp. 1073–1079, 2004.
View at: Google Scholar
L Lu, S S Chen, J Q Zhang, F J Ramires, and Y Sun, “Activation of nuclear factor- $\kappa$ B and its proinflammatory mediator cascade in the infarcted rat heart,” Biochemical and Biophysical Research Communications, vol. 321, no. 4, pp. 879–885, 2004.
View at: Google Scholar
Y-H Paik, R F Schwabe, R Bataller, M P Russo, C Jobin, and D A Brenner, “Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells,” Hepatology, vol. 37, no. 5, pp. 1043–1055, 2003.
View at: Google Scholar
A L Moreira, E P Sampaio, A Zmuidzinas, P Frindt, K A Smith, and G Kaplan, “Thalidomide exerts its inhibitory action on tumor necrosis factor $\alpha$ by enhancing mRNA degradation,” Journal of Experimental Medicine, vol. 177, no. 6, pp. 1675–1680, 1993.
View at: Google Scholar
E P Sampaio, M O Hernandez, D S Carvalho, and E N Sarno, “Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNF $\alpha$ production in vitro,” Biomedicine and Pharmacotherapy, vol. 56, no. 1, pp. 13–19, 2002.
View at: Google Scholar
J A Keifer, D C Guttridge, B P Ashburner, and A S Jr Baldwin, “Inhibition of NF- $\kappa$ B activity by thalidomide through suppression of I $\kappa$ B kinase activity,” Journal of Biological Chemistry, vol. 276, no. 25, pp. 22382–22387, 2001.
View at: Google Scholar

Copyright

Copyright © 2006 Peng Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

260

Downloads

762

Citations